Bulgaria · Delayed Price · Currency is BGN · Price in EUR Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 1.79 billion. The enterprise value is 2.35 billion.
| Market Cap | 1.79B |
| Enterprise Value | 2.35B |
Important Dates
The last earnings date was Monday, March 2, 2026.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | Dec 18, 2025 |
Share Statistics
Sopharma AD has 525.53 million shares outstanding. The number of shares has decreased by -30.63% in one year.
| Current Share Class | 525.53M |
| Shares Outstanding | 525.53M |
| Shares Change (YoY) | -30.63% |
| Shares Change (QoQ) | +41.39% |
| Owned by Insiders (%) | 9.67% |
| Owned by Institutions (%) | 0.29% |
| Float | 172.38M |
Valuation Ratios
The trailing PE ratio is 8.91.
| PE Ratio | 8.91 |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 1.82 |
| P/TBV Ratio | 2.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 96.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.67, with an EV/FCF ratio of -88.87.
| EV / Earnings | 17.60 |
| EV / Sales | 0.91 |
| EV / EBITDA | 9.67 |
| EV / EBIT | 13.83 |
| EV / FCF | -88.87 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.30 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 2.93 |
| Debt / FCF | -23.17 |
| Interest Coverage | 6.27 |
Financial Efficiency
Return on equity (ROE) is 15.52% and return on invested capital (ROIC) is 7.82%.
| Return on Equity (ROE) | 15.52% |
| Return on Assets (ROA) | 4.35% |
| Return on Invested Capital (ROIC) | 7.82% |
| Return on Capital Employed (ROCE) | 10.89% |
| Weighted Average Cost of Capital (WACC) | 4.14% |
| Revenue Per Employee | 443,809 |
| Profits Per Employee | 22,509 |
| Employee Count | 5,932 |
| Asset Turnover | 1.36 |
| Inventory Turnover | 4.19 |
Taxes
In the past 12 months, Sopharma AD has paid 15.66 million in taxes.
| Income Tax | 15.66M |
| Effective Tax Rate | 9.96% |
Stock Price Statistics
The stock price has decreased by -8.17% in the last 52 weeks. The beta is 0.04, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | -8.17% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 47.44 |
| Average Volume (20 Days) | 116,343 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.63 billion and earned 133.52 million in profits. Earnings per share was 0.39.
| Revenue | 2.63B |
| Gross Profit | 625.13M |
| Operating Income | 134.86M |
| Pretax Income | 157.24M |
| Net Income | 133.52M |
| EBITDA | 205.65M |
| EBIT | 134.86M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 71.60 million in cash and 612.87 million in debt, with a net cash position of -541.27 million or -1.03 per share.
| Cash & Cash Equivalents | 71.60M |
| Total Debt | 612.87M |
| Net Cash | -541.27M |
| Net Cash Per Share | -1.03 |
| Equity (Book Value) | 981.81M |
| Book Value Per Share | 1.81 |
| Working Capital | 249.55M |
Cash Flow
In the last 12 months, operating cash flow was 18.55 million and capital expenditures -45.00 million, giving a free cash flow of -26.45 million.
| Operating Cash Flow | 18.55M |
| Capital Expenditures | -45.00M |
| Depreciation & Amortization | 70.78M |
| Net Borrowing | 90.21M |
| Free Cash Flow | -26.45M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 23.75%, with operating and profit margins of 5.12% and 5.07%.
| Gross Margin | 23.75% |
| Operating Margin | 5.12% |
| Pretax Margin | 5.97% |
| Profit Margin | 5.07% |
| EBITDA Margin | 7.81% |
| EBIT Margin | 5.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.64%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 1.64% |
| Dividend Growth (YoY) | 205.42% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 43.16% |
| Buyback Yield | 30.63% |
| Shareholder Yield | 32.27% |
| Earnings Yield | 7.46% |
| FCF Yield | -1.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.53 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.53 |
| Piotroski F-Score | 6 |